Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Avenda Health has announced study results showing that its cancer mapping tool, Unfold AI, predicts cancer spread more accurately than MRI.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

Cleveland Clinic Abu Dhabi, in collaboration with experts from Cleveland Clinic in the U.S., performed the world’s first remotely conducted transcontinental robotic-assisted focal therapy for prostate cancer.

April 25, 2025

Vol.51 No.16

Clinical Roundup

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy.

April 11, 2025

Vol.51 No.14

Clinical Roundup

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Researchers have identified a “master regulator” gene, ZNFX1, that may act as a biomarker to help guide treatment in future clinical trials involving patients with therapy-resistant ovarian cancer, according to a study recently published in Cancer Research.

April 04, 2025

Vol.51 No.13

Building a nationally integrated cancer research and treatment network

Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.

FDA approves prostate cancer imaging agent Gozellix

FDA approved Gozellix (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), a next-generation PSMA-PET imaging agent for prostate cancer.

March 28, 2025

Vol.51 No.12

Living in disadvantaged neighborhoods influences stress-related genes, which may contribute to aggressive prostate cancer in African American men

YOU MAY BE INTERESTED IN

AI mapping technology outperforms MRI in predicting prostate cancer spread, study shows

Cleveland Clinic Abu Dhabi performs first-ever transcontinental robotic assisted focal therapy procedure for prostate cancer

UCLA test predicts which prostate cancer patients are most likely to develop long-term side effects from radiation therapy

Researchers identify “master regulator” gene that could lead to more effective ovarian cancer treatment

Building a nationally integrated cancer research and treatment network

FDA approves prostate cancer imaging agent Gozellix

Renew today!

Subscriber content

Never miss an issue!

Login